Kymera Therapeutics reported Phase Ib biomarker activity from its oral STAT6 degrader program in atopic dermatitis that the company and analysts described as 'biologics-like' and sent the stock up sharply. BioCentury coverage noted that the oral degrader produced target engagement and downstream biomarker changes consistent with meaningful pathway inhibition in patients. Kymera emphasized the signal in conference materials and a company statement. Separately, Kymera also announced positive Phase 1b results from its KT-621 oral program in eczema showing large reductions in Eczema Area and Severity Index (EASI) scores. Targeted protein degradation is a therapeutic modality that induces selective destruction of disease-driving proteins via the cell's proteasome system; Kymera's results provide an early clinical proof-of-concept for degraders in immunology.